The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Smart Stop: lenalidomide, tafasitamab, rituximab, & acalabrutinib ± chemo in newly diagnosed DLBCL
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the primary analysis of the Smart Stop trial (NCT04978584), which evaluated a four-drug combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib (LTRA) in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Dr Westin notes that the findings of this trial are highly encouraging, with the reduction or omission of chemotherapy being feasible in patients who achieve a complete response (CR) with the quadruplet regimen. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
